36 results about "Muscle dysfunction" patented technology

N,N-Disubstituted diazocycloalkanes of the formula I(R1=halogen, R2=(C3–C8)-cycloalkyl, R3=(C1–C4)-alkoxy or (C1–C4)-haloalkoxy group, m is 1 or 2 and n is 1 or 2, have affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor.

An electro-stimulation device for the treatment of anterior and posterior pelvic floor muscle dysfunction is reversibly compressible and is fully self-contained. The device requires no external power sources or control and may be inserted into the vagina or anus through the use of an applicator. In the compressed state the device may be of tampon proportions and after use may easily be removed. The device utilizes a compressible electrode component.

The invention provides an interactive type pelvic floor muscle recovering device in the technical field of medical instruments. The interactive type pelvic floor muscle recovering device comprises a myoelectricity collecting module, a muscle force collecting module, a stimulation treating module, a power circuit module, a reset circuit module and a serial communication module. The interactive type pelvic floor muscle recovering device is designed with a C2000DSP chip as the core and used for guiding a patient to correctly contract pelvic floor muscles and for independently restraining abnormal contracting of the detrusor of the bladder. The interactive type pelvic floor muscle recovering device plays a very important role in improving quality of postpartum life of women and preventing and treating postpartum uracratia, pelvic cavity viscera prolapsus and the like, can not only effectively diagnose functional disorders of the pelvic floor muscle, but also conduct rehabilitation, and has the advantages of being portable, low in power consumption and capable of conducting two-way stimulation and the like.

The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.

Provision of a drug, a quasi-drug, and a food or beverage, which are effective for senescence inhibition, mitochondrial function improvement, muscle dysfunction inhibition, muscular atrophy inhibition, prevention of a bedridden state, muscle senescence inhibition, or motor function improvement. A senescence inhibitor, a mitochondrial function-improving agent, a muscle dysfunction inhibitor, a muscular atrophy inhibitor, and an agent for preventing a bedridden state, containing a catechin as an effective ingredient. A muscle senescence inhibitor and a motor function-improving agent, containing a catechin and an amino acid as effective ingredients.

The invention provides an interactive pelvic floor muscle rehabilitation device in the technical field of medical instruments. The rehabilitation device is composed of a power supply circuit module, a myoelectricity collection module, a stimulation circuit module, a reset module and a communication module. The interactive multi-channel medical instrument designed based on a DSP chip as a core is capable of collecting a myoelectricity signal and providing diagnosis information as well as stimulating pelvic floor muscles by currents with different intensities, frequencies, and waveforms to improve the nerve muscle function and promote conduction function rehabilitation, so that the pelvic floor nerves can work normally. Therefore, the rehabilitation device has important significance in improving the living quality of women after delivery and treating post partum urinary incontinence and pelvic organ prolapse; and the pelvic floor muscle dysfunction can be diagnosed effectively and rehabilitation can be realized.

The invention discloses an information data management method of a patient suffering from muscle dysfunction. The information data management method comprises the step of: connecting an ODBC (Open Database Connectivity) with an Access database through VC++ for management, wherein information data of the patient comprise basic information, myodynamia test data, myoelectricity test data, muscular tension test data and myodynamia training data of the patient, management contents comprise the procedures of storing, deleting, inquiring and backing up the information data of the patient; the myodynamia test data, the myoelectricity test data, the muscular tension test data and the myodynamia training data are obtained through a myodynamia testing device, a myoelectricity testing device and a training device and are directly stored into the Access database; the myodynamia test data, the muscular tension test data and the myodynamia training data are reflected on a myodynamia oscillogram; the myoelectricity testing data are reflected on a myoelectricity oscillogram; and the myodynamia oscillogram and the myoelectricity oscillogram are stored by the Access database in an OLE (Object linking and Embedding) manner and can be played back. According to the invention, the myodynamia test data, the myoelectricity test data, the muscular tension test data and the myodynamia training data are stored together, thus a doctor can be helped to make a better evaluation for the muscle function of the patient.

The present invention relates to a novel alkaloid and novel bioactive alkaloid fractions derivable from Ribes preferably selected among Ribes Rubrum and Ribes nigrum; methods of manufacturing such bioactive Ribes alkaloid fractions and their use for the inhibition of IKK-β, PDE4 and / or PDE5 and in addition their promoting effect on mitochondrial biogenesis and function; their therapeutic or non-therapeutic applications as nutritive or medicinal products in the management of conditions associated with impaired mitochondrial function or IKK-β, PDE4 and / or PDE5 activity, such as inflammation, neurodegeneration, dyslipidemia, type 2 diabetes mellitus, impaired wound healing, sarcopenia and other conditions associated with muscle dysfunction or tiredness and fatigue, or where optimization of muscular or cognitive function is desired; extracts, juices or concentrates of Ribes comprising such alkaloids; compostions comprising such alkaloids, including pharmaceutical compositions, nutritive product such as functional foods and nutraceutical compositions, and cosmetic compositions and medical devices.

Disclosed herein are compositions and methods for treatment of muscle dysfunction, including diabetes. In addition, the invention relates to therapeutic compositions comprising nucleotides and / or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the treatment of skeletal musle disorders. Moreover, the invention relates to the treatment and / or prevention of pathological conditions associated with altered intracellular Ca2+ reulgation and disrupted membrane structure that occurs when the expression levels of MG29 are reduced.

This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).

This document provides methods and materials for modulating afferent nerve signals to treat medical conditions such as CHF, CHF respiration, dyspnea, peripheral vascular disease (e.g., peripheral arterial disease or venous insufficiency), hypertension (e.g., age-associated hypertension, resistant hypertension, or chronic refractory hypertension), COPD, sleep apnea, and chronic forms of lung disease where muscle dysfunction is a part of the disease pathophysiology. For example, methods and materials involved in using electrical and / or chemical techniques to block or reduce afferent nerve signals (e.g., nerve signals of group III and / or IV afferents coming from skeletal muscle and / or the kidneys) are provided.

The present invention relates to a novel alkaloid and novel bioactive alkaloid fractions derivable from Ribes preferably selected among Ribes Rubrum and Ribes nigrum; methods of manufacturing such bioactive Ribes alkaloid fractions and their use for the inhibition of IKK-β, PDE4 and / or PDE5 and in addition their promoting effect on mitochondrial biogenesis and function; their therapeutic or non-therapeutic applications as nutritive or medicinal products in the management of conditions associated with impaired mitochondrial function or IKK-β, PDE4 and / or PDE5 activity, such as inflammation, neurodegeneration, dyslipidemia, type 2 diabetes mellitus, impaired wound healing, sarcopenia and other conditions associated with muscle dysfunction or tiredness and fatigue, or where optimization of muscular or cognitive function is desired; extracts, juices or concentrates of Ribes comprising such alkaloids; compostions comprising such alkaloids, including pharmaceutical compositions, nutritive product such as functional foods and nutraceutical compositions, and cosmetic compositions and medical devices.

The present invention relates to a peptide comprising a muscle function enhancing amino acid sequence which is derived from the S100 calcium binding protein family. Furthermore, the present invention provides said peptide for medical use, in particular, for treating or preventing disorders associated with muscular malfunction, such as skeletal muscle or cardiac muscle disorders. The present invention also provides a pharmaceutical composition comprising said peptide and a method for treating or preventing disorders associated with muscular malfunction using said peptide or said pharmaceutical composition.

The present invention is directed to the treatment of muscular dysfunction or increasing muscle strength and / or decreasing muscle fatigue in a subject using a composition that includes a biguanide or a pharmaceutically acceptable salt thereof, e.g., at a low dosage.

The invention belongs to the field of myoelectricity biofeedback instruments, and particularly relates to a myoelectricity biofeedback instrument for treating pelvic floor muscle dysfunction. The myoelectricity biofeedback instrument comprises an insertion mechanism and a grip mechanism, wherein the insertion mechanism used for being inserted into the vaginal cavity of a human body is in inserted cooperation with the grip mechanism. An elastic film provided with electrode plates is driven by air blown into the inner cavity of an insertion rod by a vacuum pump to bulge outwards, so that the diameter size of the insertion rod is changed to adapt to the size change of the vaginal cavity of the human body, it is guaranteed that the electrode plates on the insertion rod inserted into the vaginal cavity of the human body can make effective contact with the inner wall of the vaginal cavity of the human body, and electromyographic signal acquisition and stimulation current treatment on muscle groups in the vaginal cavity are facilitated.

This invention provides methods, compounds and compositions for the treatment of musculoskeletal disease, muscle dysfunction, muscle-wasting disease or disorder, including hereditary myopathy, neuromuscular disease, muscular dystrophy, muscular atrophy, drug-induced myopathy, and related disease, disorder or condition that causes a decrease in muscle strength, comprising the use of heterocyclic non-peptidic compounds that act as Mas agonists and / or mimics of angiotensin 1-7.

Compounds I(R1 is an optionally substituted C1-C13 heteromonocyclic, heterobicyclic or heterotricyclic group containing from 1 to 5 heteroatoms selected from N, O and S;R2 is H, an optionally substituted monocyclic aromatic group, or a C1-C5 heteroaromatic group containing from 1 to 4 heteroatoms selected from N, O and S;R3 is an optionally substituted C1-C13 heteromonocyclic, heterobicyclic or heterotricyclic group containing from 1 to 5 heteroatoms selected from N, O and S; an optionally substituted mono-, bi- or tricyclic C6-C14 aryl group, an optionally substituted C3-C6 cycloalkyl group, or an optionally substituted C3-C6 cycloalkenyl group;each R4, independently for each position capable of substitution, is H or C1-C6 alkyl;R5 is H, halogen or C1-C6 alkyl;m is 0, 1 or 2; n is 0, 1 or 2; p is 0, 1, 2, 3, 4, 5, or 6; and is an optional double bond)and their enantiomers, diastereomers, N-oxides and pharmaceutically acceptable salts, and pharmaceutical compositions containing them, are useful for the treatment of neuromuscular dysfunction of the lower urinary tract and also for the treatment of gastrooesophageal reflux disease; anxiety disorder; abuse, substance dependence and substance withdrawal disorders; neuropathic pain disorder, migraine and fragile X syndrome disorders.

A neurophysiological method of treating muscular dysfunction caused by a neurological disorder, such as Parkinson's Disease, includes applying a predetermined pressure to the patient, so as to cause pain inhibition that blocks response to a targeted muscle at the spinal cord level, and translating the patient through a passive range of motion, while causing the pain.

Disclosed herein are compositions and methods for treatment of muscle dysfunction (including sarcopenia) and other diseases involving skeletal muscle, including age-related muscle dysfunction. In addition, the invention relates to therapeutic compositions comprising nucleotides and / or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the treatment of skeletal muscle disorder, including those related to thr normal aging process. Moreover, the invention relates to the treatment and / or prevention of pathological conditions associated with altered intracellular Ca2+ regulation and disrupted membrane structure that occurs when the expression levels of MG29 are reduced.

The present invention relates to a peptide comprising a muscle function enhancing amino acid sequence which is derived from the S100 calcium binding protein family. Furthermore, the present invention provides said peptide for medical use, in particular, for treating or preventing disorders associated with muscular malfunction, such as skeletal muscle or cardiac muscle disorders. The present invention also provides a pharmaceutical composition comprising said peptide and a method for treating or preventing disorders associated with muscular malfunction using said peptide or said pharmaceutical composition.

The invention discloses a rehabilitation training device for cyclopharyngeal muscle dysfunction, which belongs to the field of medical treatment, and comprises an outer tube, the bottom end of the outer tube is fixedly connected with an elastic bag communicated with the outer tube, the bottom of the inner side of the elastic bag is fixedly connected with an inner tube, and the top end of the inner tube extends to the inner side of the outer tube. The top end of the inner pipe penetrates through and is slidably connected to the outer side of the outer pipe, and ventilation blocks which are arranged at equal intervals are fixedly connected to the outer portion of the inner pipe. The elastic bag can be conveniently collected into the inner side of the outer tube through the sliding inner tube, the elastic bag can be conveniently conveyed to the esophagus of a patient, the situation that the elastic bag continuously scrapes the inner wall of the esophagus is avoided, cold water enters the inner tube, the outer tube is pulled away from the cold water, the cold water in the elastic bag is conveniently replaced in time, and the cyclopharyngeal muscle is more effectively stimulated; rehabilitation training can be carried out on the patient with the cyclopharyngeal muscle dysfunction in a passive and active combined passive mode, and therefore using is convenient.

The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.

The invention discloses a traditional Chinese medicine for treating benign prostatic hyperplasia with kidney deficiency and blood stasis and a preparation method for bladder detrusor dysfunction. The traditional Chinese medicine includes the following raw materials: Cuscuta 15-30g, Cornus officinale 14-16g, Golden Cherry 14-16g, burnt dragon bone 20-30g, leek seeds 15-20g, astragalus 30-45g, amber 2.5-3.5g, blanched leech 3-5g, Aphrodisiac 15-20g, mulberry octopus 10-15g, soybean herb 20‑30g, Sichuan Achyranthes 14‑16g. The invention is made of pure natural raw materials and Chinese medicines. Various medicines are organically coordinated, synergistic, reasonably formulated, rich in raw materials, simple in method, convenient to take, good in curative effect and low in cost. It is an ideal method for treating benign prostatic hyperplasia and bladder pressure. A major innovation in the treatment of urinary muscle dysfunction.

Disclosed herein are pharmaceutical agents and compositions that activate integrin heterodimers that contain beta-1 integrin protein that specifically bind laminin protein. Such agents and compositions are useful for treating diseases related to muscle malfunction, including muscular dystrophies.

This document provides methods and materials for modulating afferent nerve signals to treat medical conditions such as CHF, CHF respiration, dyspnea, peripheral vascular disease (e.g., peripheral arterial disease or venous insufficiency), hypertension (e.g., age-associated hypertension, resistant hypertension, or chronic refractory hypertension), COPD, sleep apnea, and chronic forms of lung disease where muscle dysfunction is a part of the disease pathophysiology. For example, methods and materials involved in using electrical and / or chemical techniques to block or reduce afferent nerve signals (e.g., nerve signals of group III and / or IV afferents coming from skeletal muscle and / or the kidneys) are provided.

This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).